- Home
- ACIC vs PCRX Comparison
ACIC vs PCRX Comparison
Compare ACIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- PCRX
- Stock Information
- Founded
- ACIC 1999
- PCRX 2006
- Country
- ACIC United States
- PCRX United States
- Employees
- ACIC N/A
- PCRX N/A
- Industry
- ACIC Property-Casualty Insurers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- PCRX Health Care
- Exchange
- ACIC Nasdaq
- PCRX Nasdaq
- Market Cap
- ACIC 556.0M
- PCRX 1.2B
- IPO Year
- ACIC N/A
- PCRX 2011
- Fundamental
- Price
- ACIC $11.14
- PCRX $26.65
- Analyst Decision
- ACIC Buy
- PCRX Buy
- Analyst Count
- ACIC 1
- PCRX 6
- Target Price
- ACIC $16.00
- PCRX $30.00
- AVG Volume (30 Days)
- ACIC 167.6K
- PCRX 617.5K
- Earning Date
- ACIC 11-05-2025
- PCRX 11-05-2025
- Dividend Yield
- ACIC 4.49%
- PCRX N/A
- EPS Growth
- ACIC 14.01
- PCRX N/A
- EPS
- ACIC 1.63
- PCRX N/A
- Revenue
- ACIC $320,072,000.00
- PCRX $705,848,000.00
- Revenue This Year
- ACIC $4.91
- PCRX $7.36
- Revenue Next Year
- ACIC $4.16
- PCRX $10.07
- P/E Ratio
- ACIC $6.83
- PCRX N/A
- Revenue Growth
- ACIC 33.90
- PCRX 2.25
- 52 Week Low
- ACIC $8.82
- PCRX $13.42
- 52 Week High
- ACIC $15.08
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- ACIC 53.90
- PCRX 57.10
- Support Level
- ACIC $10.71
- PCRX $26.22
- Resistance Level
- ACIC $11.27
- PCRX $27.50
- Average True Range (ATR)
- ACIC 0.34
- PCRX 0.93
- MACD
- ACIC -0.02
- PCRX -0.14
- Stochastic Oscillator
- ACIC 38.74
- PCRX 50.75
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.